Cart
sales@molnova.com
BAY-1816032
CAS No. 1891087-61-8
BAY-1816032( BAY1816032 )
Catalog No. M12963 CAS No. 1891087-61-8
BAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 115 | Get Quote |
|
| 10MG | 192 | Get Quote |
|
| 25MG | 383 | Get Quote |
|
| 50MG | 565 | Get Quote |
|
| 100MG | 806 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBAY-1816032
-
NoteResearch use only, not for human use.
-
Brief DescriptionBAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM.
-
DescriptionBAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM, displays excellent selectivity on a panel of 395 kinases; abrogates nocodazole-induced Thr-120 phosphorylation of the major BUB1 target protein histone H2A in HeLa cells with IC50 of 29 nM, induces lagging chromosomes and mitotic delay, inhibits proliferation of various tumor cell lines with mean IC50 of 1.4 uM; demonstrates synergy or additivity with paclitaxel or docetaxel both in vitro and in vivo.
-
In Vitro——
-
In Vivo——
-
SynonymsBAY1816032
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1891087-61-8
-
Formula Weight534.524
-
Molecular FormulaC27H24F2N6O4
-
Purity>98% (HPLC)
-
SolubilityDMSO : 25 mg/mL 46.77 mM; H2O : < 0.1 mg/mL
-
SMILESCOC1=CN=C(N=C1NC2=C(C=NC=C2)OC)C3=NN(C4=CC=CC=C43)CC5=C(C=C(C=C5F)OCCO)F
-
Chemical Name2-[3,5-Difluoro-4-[[3-[5-methoxy-4-[(3-methoxy-4-pyridinyl)amino]-2-pyrimidinyl]-1H-indazol-1-yl]methyl]phenoxy]ethanol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gerhard Siemeister, et al. Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity. AACR. DOI: 10.1158/1538-7445.
2.?Siemeister G, et al. Clin Cancer Res. 2018 Nov 14. pii: clincanres.0628.2018.
molnova catalog
related products
-
CCT-244747
A novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor with biochemical IC50 of 8 nM; displays 75-fold selectivity against FLT3 and >1,000-fold selectivity against CHK2 and CDK1.
-
Tuvusertib
Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 μΜ) with selective and potentially antitumor activity.
-
PV-1019
A potent, ATP-competitive and highly selective Chk2 inhibitor with IC50 of 138 nM.
